Animal models and intestinal drug transport

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 4, 2008, Pages 347-361

  Glaeser, Hartmut ^a   Fromm, Martin F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ABC transporter; Absorption; Animal models; Bioavailability; Drug transporter; Elimination; Intestine; Uptake transporter

Indexed keywords

4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CEFALEXIN; CYCLOSPORIN A; DEXAMETHASONE; DIGOXIN; ELACRIDAR; ETOPOSIDE; EZETIMIBE; GEPRAFLOXACIN; GLYCOPROTEIN P; IVERMECTIN; LOPERAMIDE; METFORMIN; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC CATION TRANSPORTER 1; PACLITAXEL; PEPTIDE TRANSPORTER 1; PRAVASTATIN; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT INTERLEUKIN 2; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

AREA UNDER THE CURVE; BILIARY EXCRETION; BIOLOGICAL MODEL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG POTENCY; DRUG POTENTIATION; DRUG TRANSPORT; DRUG UPTAKE; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; INTESTINE ABSORPTION; KIDNEY TUBULE EXCRETION; KNOCKOUT GENE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; INTESTINAL ABSORPTION; INTESTINES; MEMBRANE TRANSPORT PROTEINS; MICE; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

ANIMALIA;

EID: 44349194371     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.4.347     Document Type: Review

References (98)

1. Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18:621-6
2. Gonzalez FJ, Kimura S. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis. Cancer Lett 1999;143:199-204
3. Gonzalez FJ. Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev 2003;35:319-35
4. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-45
5. Hochman JH, Chiba M, Nishime J, et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000;292:310-8
6. Cummins CL, Salphati L, Reid MJ, et al. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003;305:306-14
7. Drescher S, Glaeser H, Mürdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003;73:223-31
8. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003;33(Suppl 2):6-9
9. Lee W, Lockhart AC, Kim RB, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005;10:104-11
10. Robey RW, Polgar O, Deeken J, et al. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007;26:39-57
11. Merino V, Jimenez-Torres NV, Merino-Sanjuan M. Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr Drug Deliv 2004;1:203-12
12. Fischer V, Einolf HJ, Cohen D. Efflux transporters and their clinical relevance. Mini Rev Med Chem 2005;5:183-95
13. Gottesman MM, Ambudkar SV, Cornwell MM, et al. Multidrug resistance transporter. In: Schultz SG, editor, Molecular biology of membrane transport disorders. New York: Plenum Press; 1996. p. 243-57
14. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
15. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8:161-70
16. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-29
17. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
18. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70
19. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46
20. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63
21. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63:5538-43
22. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64
23. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-golycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-37
24. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6
25. Büchler M, König J, Brom M, et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996;271:15091-98
26. Ito K, Suzuki H, Hirohashi T, et al. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 1997;272:G16-22
27. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997;25:1539-42
28. König J, Nies AT, Cui Y, et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461:377-94
29. Fromm MF, Kauffmann HM, Fritz P, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000;157:1575-80
30. Tsujii H, König J, Rost D, et al. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999;117:653-60
31. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 1997;57:1934-8
32. Yamazaki M, Akiyama S, Ni'inuma K, et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 1997;25:1123-9
33. Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5
34. Ishizuka H, Konno K, Naganuma H, et al. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 1997;280:1304-11
35. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502
36. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87
37. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705
38. Mayer U, Wagenaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 1996;119:1038-44
39. Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997;100:2430-36
40. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94:4028-33
41. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031-5
42. Lehne G, Morkrid L, den Boer M, et al. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int J Clin Pharmacol Ther 2000;38:187-95
43. Leahey EB Jr, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA 1978;240:533-4
44. Doering W, Konig E. The influence of quinidine on serum digoxin concentrations (author's transl). Med Klin 1978;73:1085-8
45. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-7
46. Igel S, Drescher S, Murdter T, et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet 2007;46:777-85
47. Ogihara T, Kamiya M, Ozawa M, et al. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet 2006;21:238-44
48. Veau C, Faivre L, Tardivel S, et al. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 2002;302:742-50
49. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-44
50. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33
51. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99:15649-54
52. Chen AY, Yu C, Potmesil M, et al. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991;51:6039-44
53. Allen JD, Van Dort SC, Buitelaar M, et al. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-golycoprotein. Cancer Res 2003;63:1339-44
54. Polli JW, Baughman TM, Humphreys JE, et al. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab Dispos 2004;32:722-6
55. van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine. Cancer Res 2003;63:6447-52
56. Kondo C, Onuki R, Kusuhara H, et al. Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm Res 2005;22:613-8
57. Adachi Y, Suzuki H, Schinkel AH, et al. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol 2005;67:923-8
58. Jansen PL, Peters WH, Lamers WH. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985;5:573-9
59. Kurisu H, Kamisaka K, Koyo T, et al. Organic anion transport study in mutant rats with autosomal recessive conjugated hyperbilirubinemia. Life Sci 1991;49:1003-11
60. Paulusma CC, Oude Elferink RP. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med 1997;75:420-8
61. Jansen PL, van Klinken JW, van Gelder M, et al. Preserved organic anion transport in mutant TR- rats with a hepatobiliary secretion defect. Am J Physiol 1993;265:G445-52
62. Guhlmann A, Krauss K, Oberdorfer F, et al. Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography. Hepatology 1995;21:1568-75
63. Huber M, Guhlmann A, Jansen PL, et al. Hereditary defect of hepatobiliary cysteinyl leukotriene elimination in mutant rats with defective hepatic anion excretion. Hepatology 1987;7:224-8
64. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007;453:643-59
65. Gotoh Y, Suzuki H, Kinoshita S, et al. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/ multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 2000;292:433-9
66. Dietrich CG, de Waart DR, Ottenhoff R, et al. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis 2001;22:805-11
67. Dietrich CG, de Waart DR, Ottenhoff R, et al. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 2001;59:974-80
68. Akao T, Sakashita Y, Hanada M, et al. Enteric excretion of baicalein, a flavone of Scutellariae Radix, via glucuronidation in rat: involvement of multidrug resistance-associated protein 2. Pharm Res 2004;21:2120-6
69. Naruhashi K, Tamai I, Inoue N, et al. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 2002;46:344-9
70. Hirohashi T, Suzuki H, Ito K, et al. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 1998;53:1068-75
71. König J, Rost D, Cui Y, et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999;29:1156-63
72. Jager W, Sartori M, Herzog W, et al. Genistein metabolism in liver microsomes of Wistar and mutant TR(-)-rats. Res Commun Mol Pathol Pharmacol 1998;100:105-16
73. Johnson BM, Zhang P, Schuetz JD, et al. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 2006;34:556-62
74. Chu XY, Strauss JR, Mariano MA, et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 2006;317:579-89
75. Kivistö KT, Grisk O, Hofmann U, et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. Drug Metab Dispos 2005;33:1593-6
76. Oswald S, Westrup S, Grube M, et al. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 2006;318:1293-9
77. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003;33(Suppl 2):1-5
78. König J, Seithel A, Gradhand U, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006;372:43-43
79. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005;28:789-801
80. Anzai N, Kanai Y, Endou H. Organic anion transporter family: current knowledge. J Pharmacol Sci 2006;100:411-26
81. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51
82. Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 2004;447:610-8
83. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70
84. Lee W, Smith LH, Gervasini G, et al. Identification of nonsynonomous polymorphisms of human organic anion transporting polypeptide-A (OATP-A) associated with altered transport activity [abstract]. Clin Pharmacol Ther 2004;75:351
85. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8
86. König J, Cui Y, Nies AT, et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278:G156-64
87. König J, Cui Y, Nies AT, et al. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-8
88. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003;1609:1-18
89. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004;447:653-65
90. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004;308:2-9
91. Gründemann D, Gorboulev V, Gambaryan S, et al. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994;372:549-52
92. Jonker JW, Wagenaar E, Mol CA, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 2001;21:5471-7
93. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-5
94. Meyer-Wentrup F, Karbach U, Gorboulev V, et al. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun 1998;248:673-8
95. Müller J, Lips KS, Metzner L, et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005;70:1851-60
96. Groneberg DA, Doring F, Eynott PR, et al. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol Gastrointest Liver Physiol 2001;281:G697-704
97. Chu XY, Sanchez-Castano GP, Higaki K, et al. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther 2001;299:575-82
98. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24